Provided by Tiger Trade Technology Pte. Ltd.

Enliven Treateutics

54.32
-1.9100-3.40%
Post-market: 54.320.00000.00%16:59 EDT
Volume:995.81K
Turnover:54.45M
Market Cap:3.98B
PE:-32.42
High:57.00
Open:57.00
Low:54.12
Close:56.23
52wk High:62.32
52wk Low:14.79
Shares:73.27M
Float Shares:61.73M
Volume Ratio:0.94
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6753
EPS(LYR):-1.8300
ROE:-15.31%
ROA:-11.00%
PB:4.45
PE(LYR):-29.68

Loading ...

Enliven Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $60

THOMSON REUTERS
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

Enliven initiated with a Buy at Stifel

TIPRANKS
·
Jun 09

Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

TIPRANKS
·
Jun 02

Enliven Therapeutics presents at TD Cowen oncology summit fireside chat

Reuters
·
May 22

Enliven CMO Helen Louise Collins sells USD 191,757 in common shares

Reuters
·
May 21

Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

TIPRANKS
·
May 16

Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress

TIPRANKS
·
May 13

Stock Track | Enliven Therapeutics Soars 5.35% on Positive Clinical Data, Analyst Initiation, and Earnings Beat

Stock Track
·
May 12

Enliven presents updated Phase 1 ELVN-001 data in CML at EHA 2026

Reuters
·
May 12

Enliven Therapeutics Announces Oral Presentation at the Eha 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for Elvn-001 in Cml

THOMSON REUTERS
·
May 12

Enliven Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis

Reuters
·
May 12

Enliven Therapeutics Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $80

THOMSON REUTERS
·
May 12

Enliven initiated with a Buy at Guggenheim

TIPRANKS
·
May 12

Enliven price target raised to $59 from $41 at Goldman Sachs

TIPRANKS
·
May 09

Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029

TIPRANKS
·
May 08

Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

TIPRANKS
·
May 08

Enliven Therapeutics Q1 net loss narrows as R&D spending reduces

Reuters
·
May 08

Enliven Q1 FY26 net loss narrows to $23.6 million###

Reuters
·
May 08